A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells

Biochemical and Biophysical Research Communications

Volumn 453, Issue 4, 2014, Pages 798-803

  Kobayashi, Eiji ^a   Kishi, Hiroyuki ^a   Ozawa, Tatsuhiko ^a   Hamana, Hiroshi ^a   Nakagawa, Hidetoshi ^b   Jin, Aishun ^a,c   Lin, Zhezhu ^a,d   Muraguchi, Atsushi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

Author keywords

CAR; CTL; NK cell; TRAIL

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; DEATH RECEPTOR 4; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; APOPTOSIS REGULATORY PROTEIN; ONCOPROTEIN; TNFRSF10A PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER PATIENT; CELL CULTURE; CELL DEATH; CELL SURFACE; CELL TYPE; CROSS LINKING; CYTOTOXICITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; JURKAT CELL LINE; MULTIPLE CANCER; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PHENOTYPE; TARGET CELL; TUMOR CELL; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; HUMANS; JURKAT CELLS; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, FUSION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84909989344     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.10.024     Document Type: Article

References (23)

1. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh, and D.H. Lynch Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat. Med. 5 1999 157 163
2. A. Ashkenazi Targeting death and decoy receptors of the tumour-necrosis factor superfamily Nat. Rev. Cancer 2 2002 420 430
3. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh, and R.H. Schwall Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 104 1999 155 162
4. G.V. Georgakis, Y. Li, R. Humphreys, M. Andreeff, S. O'Brien, M. Younes, A. Carbone, V. Albert, and A. Younes Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death Br. J. Haematol. 130 2005 501 510
5. L. Pukac, P. Kanakaraj, R. Humphreys, R. Alderson, M. Bloom, C. Sung, T. Riccobene, R. Johnson, M. Fiscella, A. Mahoney, J. Carrell, E. Boyd, X.T. Yao, L. Zhang, L. Zhong, A. von Kerczek, L. Shepard, T. Vaughan, B. Edwards, C. Dobson, T. Salcedo, and V. Albert HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo Br. J. Cancer 92 2005 1430 1441
6. A. Jin, T. Ozawa, K. Tajiri, Z. Lin, T. Obata, I. Ishida, H. Kishi, and A. Muraguchi Generation of TRAIL-receptor 1-specific human monoclonal Ab by a combination of immunospot array assay on a chip and human Ab-producing mice Eur. J. Immunol. 40 2010 3591 3593
7. I. Ishida, K. Tomizuka, H. Yoshida, T. Tahara, N. Takahashi, A. Ohguma, S. Tanaka, M. Umehashi, H. Maeda, C. Nozaki, E. Halk, and N. Lonberg Production of human monoclonal and polyclonal antibodies in TransChromo animals Cloning Stem Cells 4 2002 91 102
8. T.S. Park, S.A. Rosenberg, and R.A. Morgan Treating cancer with genetically engineered T cells Trends Biotechnol. 29 2011 550 557
9. M. Sadelain, R. Brentjens, and I. Riviere The promise and potential pitfalls of chimeric antigen receptors Curr. Opin. Immunol. 21 2009 215 223
10. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc. Natl. Acad. Sci. U.S.A. 86 1989 10024 10028
11. D.H. Aggen, A.S. Chervin, T.M. Schmitt, B. Engels, J.D. Stone, S.A. Richman, K.H. Piepenbrink, B.M. Baker, P.D. Greenberg, H. Schreiber, and D.M. Kranz Single-chain ValphaVbeta T-cell receptors function without mispairing with endogenous TCR chains Gene Ther. 19 2012 365 374
12. R.J. Brentjens, E. Santos, Y. Nikhamin, R. Yeh, M. Matsushita, K. La Perle, A. Quintas-Cardama, S.M. Larson, and M. Sadelain Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts Clin. Cancer Res. 13 2007 5426 5435
13. J.D. Stone, D.H. Aggen, A. Schietinger, H. Schreiber, and D.M. Kranz A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs) Oncoimmunology 1 2012 863 873
14. Z. Lin, A. Jin, T. Ozawa, K. Tajiri, T. Obata, I. Ishida, F. Jin, H. Kishi, and A. Muraguchi Post-translational modification of TRAIL receptor type 1 on various tumor cells and the susceptibility of tumors to TRAIL-induced apoptosis Biochem. Biophys. Res. Commun. 395 2010 251 257
15. E. Kobayashi, E. Mizukoshi, H. Kishi, T. Ozawa, H. Hamana, T. Nagai, H. Nakagawa, A. Jin, S. Kaneko, and A. Muraguchi A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days Nat. Med. 19 2013 1542 1546
16. P. Schneider, M. Thome, K. Burns, J.L. Bodmer, K. Hofmann, T. Kataoka, N. Holler, and J. Tschopp TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB Immunity 7 1997 831 836
17. S. Shresta, D.M. MacIvor, J.W. Heusel, J.H. Russell, and T.J. Ley Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells Proc. Natl. Acad. Sci. U.S.A. 92 1995 5679 5683
18. B. Lowin, M.C. Peitsch, and J. Tschopp Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity Curr. Top. Microbiol. Immunol. 198 1995 1 24
19. M. Suzuki, A. Yamanoi, Y. Machino, E. Kobayashi, K. Fukuchi, M. Tsukimoto, S. Kojima, J. Kohroki, K. Akimoto, and Y. Masuho Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcgammaRIIIA Biochem. Biophys. Res. Commun. 436 2013 519 524
20. B.T. Gemlo, M.A. Palladino Jr., H.S. Jaffe, T.P. Espevik, and A.A. Rayner Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells Cancer Res. 48 1988 5864 5867
21. J.S. Bridgeman, R.E. Hawkins, S. Bagley, M. Blaylock, M. Holland, and D.E. Gilham The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex J. Immunol. 184 2010 6938 6949
22. E. Vivier, D.H. Raulet, A. Moretta, M.A. Caligiuri, L. Zitvogel, L.L. Lanier, W.M. Yokoyama, and S. Ugolini Innate or adaptive immunity? The example of natural killer cells Science 331 2011 44 49
23. T. Tonn, S. Becker, R. Esser, D. Schwabe, and E. Seifried Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92 J. Hematother. Stem Cell Res. 10 2001 535 544